{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2020"],"condition":["Advanced colorectal cancer or stomach cancer"],"disease":["Advanced Colorectal Cancer Or Stomach Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2699928"],"location":["China"],"study_start_month":["11"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"A prospective, multi-center, single-arm, open phase Ib clinical study of safety, tolerability and preliminary efficacy of anlotinib combined with duvalizumab in patients with advanced gastric or colorectal cancer who have failed second-line treatment","description":"Interventions: experimental group:Anlotinib combined with Duvalizumab\nPrimary outcome(s): DLT\nStudy Design: Single arm","dates":{"creation":"2020-11-15"},"accession":"2699928","cross_references":{"Chinese Clinical Trial Register":["ChiCTR2000039730"]}}